184Curated trials
Enterprise Evidence Report · NR-REPORT-V2.0
South Korea
Neuroscience Intelligence
South Korea neuroscience evidence report: current clinical, research, institution and source-linked intelligence.
Evidence rank #13 of 50 · Data maturity A · Research score 41.8 · Data confidence 100.0 / 100 · Snapshot 2026-10-29 06:18 UTC.
49Recruiting trials
223Publications
102Institutions
Executive interpretation
South Korea ranks #13 in the current NeuroRisk evidence-ranked market layer. This ranking summarizes indexed clinical, publication and institution evidence; it is not a probability of commercial success and not an investment recommendation.
Methodology status
Methodology NR-REPORT-V2.0. Clinical metrics and NCT evidence use only records classified as in_scope or related; out_of_scope records remain preserved outside these analytical counts. No synthetic ML confidence is presented as scientific probability. Counts and source links below are tied to the generation snapshot.
Methodology →Leading sponsors
Merck Sharp & Dohme LLC2513 recruiting
Seoul National University Hospital141 recruiting
Hoffmann-La Roche113 recruiting
Samsung Medical Center80 recruiting
Eli Lilly and Company71 recruiting
Eisai Korea Inc.50 recruiting
GlaxoSmithKline40 recruiting
Boehringer Ingelheim40 recruiting
Pfizer41 recruiting
Yonsei University41 recruiting
Disease activity
Alzheimers43trials
Parkinsons38trials
Epilepsy20trials
Stroke17trials
Depression9trials
Autism9trials
Schizophrenia8trials
Neuromuscular7trials
Adhd5trials
Migraine Headache5trials
Research institutions
Anyang UniversityOpenAlexlinked institution
Dankook UniversityOpenAlexlinked institution
Ulsan CollegeOpenAlexlinked institution
Kangbuk Samsung HospitalOpenAlexlinked institution
Korea Basic Science InstituteOpenAlexlinked institution
National Research Foundation of KoreaOpenAlexlinked institution
Ulsan National Institute of Science and TechnologyOpenAlexlinked institution
Samsung Biomedical Research InstituteOpenAlexlinked institution
SNUH SMG-SNU Boramae Medical CenterOpenAlexlinked institution
Seoul Metropolitan GovernmentOpenAlexlinked institution
Clinical evidence trail
NCT07764874Unilateral and Staged Bilateral Pallidothalamic Tractotomy Using Exablate MRgFUS in Advanced Parkinson's Disease.NOT_YET_RECRUITING
NCT07728864Sexuality and Relationship Education for Autistic Adults: Our Love, Our StyleACTIVE_NOT_RECRUITING
NCT07629115A Long-Term Follow-up Study of the Severe Parkinson's Disease Patients Administered the IPS101A Gene Therapy Product.RECRUITING
NCT07589595A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)RECRUITING
NCT07529574Efficacy and Safety of a Theta Burst Stimulation Protocol of Repetitive Transcranial Magnetic Stimulation in Treatment-Resistant DepressionNOT_YET_RECRUITING
NCT07496021Safety and Efficacy of L. Lactis CKDB001 in Subjects With Early Alzheimer's DiseaseRECRUITING
NCT07252739KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)RECRUITING
NCT07216703A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)RECRUITING
NCT07174310A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's DiseaseRECRUITING
Research evidence trail
PUBMEDMultimodal machine learning model integrating electroencephalography, heart rate variability and clinical measures for distinguishing major psychiatric disorders.2027-01-01
PUBMEDMental health risk stratification using heart rate variability and prefrontal electroencephalography: eXtreme gradient boosting-based classifier and latent class analysis-based subtyping.2027-01-01
PUBMEDEscherichia coli hns and methylglyoxal link gut microbial metabolism to host neuronal gene regulation in Parkinson's disease.2026-12-31
PUBMEDAssociations between human oxytocin receptor gene promoter DNA methylation and brain structural connectome in panic disorder in Korea.2026-12-15
PUBMEDPreliminary clinical changes during use of a personalized video-based mobile intervention for community-dwelling individuals with severe mental illness: An exploratory randomized crossover trial.2026-12-01
PUBMEDUnraveling the Genotype-Phenotype Landscape of Kleefstra Syndrome Through EHMT1 Variant Analysis.2026-12-01
PUBMEDA transdiagnostic framework for neurological intervention in maladaptive repetitive behaviors.2026-12-01
PUBMEDMapping topological abnormalities in cortical similarity networks to schizophrenia-associated gene expression.2026-12-01
PUBMEDGraph neural network-based modeling of functional brain connectivity in autism spectrum disorder using the ABIDE-I and II datasets.2026-12-01
PUBMEDDifferential linguistic patterns across Rorschach, TAT, and SCT in individuals with PTSD.2026-12-01
PUBMEDTRPA1 antagonism reveals sex-specific mechanisms in morphine withdrawal-induced negative emotional behavior via dopaminergic pathway.2026-11-15
World Bank context
Macro indicators are shown only where a timestamped World Bank source row exists. Latest collection in this report: 2026-10-24 04:18 UTC. They are context, not NeuroRisk predictions.
Sources and provenance
ClinicalTrials.gov provides NCT evidence. PubMed/NCBI and OpenAlex provide research metadata. OpenAlex links institutions. World Bank indicators are included only when an explicit source row and year exist. NeuroRisk transformations add normalization, ranking and graph connections.
Limitations
Indexed corpus counts are not guaranteed exhaustive global totals. Scores are comparative decision-support signals. This report is not medical advice, regulatory advice, patent clearance, an investment recommendation or a guarantee of outcome.